Related Experiment Video
Updated: Jul 17, 2026

10:32
Optimized Protocols for Mycobacterium leprae Strain Management: Frozen Stock Preservation and Maintenance in Athymic Nude Mice
Published on: March 23, 2014
Treating leprosy: an Erb-al remedy?
1MRC Laboratory for Molecular Cell Biology and the Department of Biochemistry, University College London, Gower Street, London WC1E 6BT, UK.
Trends in Pharmacological Sciences
|February 6, 2007
Summary
Mycobacterium leprae binding to ErbB2 on Schwann cells directly causes demyelination via the Ras-Raf-MEK-ERK pathway. This finding offers insights into leprosy treatment and nerve injury parallels.
Area of Science:
- Neuroscience
- Microbiology
- Cell Biology
Background:
- Leprosy, caused by Mycobacterium leprae, affects the peripheral nervous system.
- M. leprae infection leads to demyelination of Schwann cells.
- The precise molecular mechanisms of M. leprae-induced demyelination are under investigation.
Purpose of the Study:
- To elucidate the direct mechanism by which M. leprae induces demyelination in Schwann cells.
- To identify the specific bacterial components and host cell receptors involved in this process.
- To explore potential therapeutic targets for leprosy-related nerve damage.
Main Methods:
- Investigated the interaction between M. leprae and Schwann cells.
- Utilized receptor tyrosine kinase ErbB2 as a focal point for M. leprae binding.
- Analyzed the activation of the Ras-Raf-MEK-ERK signaling pathway following bacterial-receptor interaction.
Main Results:
- M. leprae directly binds to the ErbB2 receptor on Schwann cells.
- This binding event triggers the activation of the Ras-Raf-MEK-ERK signaling cascade.
- The activated pathway mediates the demyelination process in Schwann cells.
Conclusions:
- M. leprae-induced demyelination is a direct consequence of its interaction with Schwann cell ErbB2.
- The Ras-Raf-MEK-ERK pathway is a key mediator of M. leprae's pathogenic effects on peripheral nerves.
- Findings suggest potential therapeutic strategies targeting the ErbB2 pathway for leprosy treatment and highlight similarities with nerve injury and cancer signaling.
Related Concept Videos
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
